BIOGEN RESPONDS TO COVERAGE RECOMMENDATION BY THE CANADIAN DRUG EXPERT COMMITTEE (CDEC) FOR SPINRAZA, THE ONLY TREATMENT APPROVED FOR TREATMENT OF 5Q SPINAL MUSCULAR ATROPHY (SMA)

BIOGEN RESPONDS TO COVERAGE RECOMMENDATION BY THE CANADIAN DRUG EXPERT COMMITTEE (CDEC) FOR SPINRAZA, THE ONLY TREATMENT APPROVED FOR TREATMENT OF 5Q SPINAL MUSCULAR ATROPHY (SMA) Ottawa – December 22, 2017 – Today the Canadian Drug Expert Committee (CDEC) made public its recommendation to the Common Drug Review (CDR) participating drug plans to reimburse SPINRAZA…

next steps following Health Canada’s approval of SPINRAZA™ (nusinersen).

Dear members of the SMA community, In response to your request for information, we would like to provide you with an update on Biogen’s SMA360 Canada Patient Support Program and the next steps following Health Canada’s approval of SPINRAZA™ (nusinersen). The SMA360 Canada Patient Support Program has been developed to be available for patients and…

Update from Dr. Rashmi Kothary

Cure SMA Canada Funded Canadian Researcher Dr. Rashmi Kothar Ottawa Hospital Research Institute Biosketch: Dr. Kothary is the Deputy Scientific Director and Senior Scientist at the Ottawa Hospital Research Institute (OHRI). He received a Ph.D. in Biochemistry from the University of British Columbia and pursued postdoctoral research in the laboratories of Dr. Janet Rossant at…